A b s t r a c t
No single biologic marker is used in the routine diagnosis of hepatocellular carcinoma (HCC). We screened for potential biomarkers in 142 samples, including samples from 60 patients with HCC, 36 patients with hepatic disease other than HCC, and 46 age-and sex-matched healthy volunteers. Pretreated samples were analyzed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) combined with weak cationic exchange magnetic beads. The diagnostic pattern with a panel of 4 potential protein biomarkers of a massto-charge (m/z) ratio of
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, with 626,000 new cases occurring in 2002. 1 Surgical resection remains the primary treatment of choice, but because of the very high rate of metastasis and poor prognosis, the number of deaths is almost the same as the number of new cases (598,000) occurring each year worldwide. 2 In recent years, an increasing incidence and mortality rate of HCC have also been observed in Western industrialized countries. 3, 4 Most studies on the etiology of HCC suggest that risk factors such as hepatitis B virus (HBV), cirrhosis, dietary aflatoxin B1 intake, and alcohol abuse are responsible for almost all HCC development. HBV and hepatitis C virus are attributed to more than 70% of HCC development worldwide. 5 In high-incidence areas of China, more than 90% of HCC cases are reported to have an HBV background. 6 Liver cirrhosis, regardless of its etiology, is recognized as the most powerful independent risk factor for HCC, and about 55% to 85% of cases finally develop into HCC with poor prognosis. 7, 8 Although much is known about the effects of the aforementioned etiologic agents on the development of HCC, detailed pathologic mechanisms of HCC remain to be unequivocally defined, mainly owing to its complex multigene and multifactorial involvement and the strong associations with hepatitis and cirrhosis.
Presently, early surgical interventions, including hepatectomy and percutaneous radiofrequency ablation, are the best hope for a clinical cure of HCC. Unfortunately, many cases of HCC exhibit intrahepatic and distant metastasis at the time of diagnosis, missing the optimal opportunity for surgical resection. This indirectly indicates no ideal tumor markers can be recommended for early detection or differential diagnosis of HCC. Thus, discovering more HCCassociated proteins and identifying a single or a set of reliable, noninvasive new biomarkers is one of the best options for improving the diagnostic efficiency for HCC.
A new method for diagnosing the early stage of HCC remains an urgent need in clinical practice. In this study, we used proteomic approaches to identify relevant biomarkers that could replace invasive and nonspecific tests for the early diagnosis of HCC. This is a relatively new technique, which lacks the disadvantages of 2-dimensional gel electrophoresis for proteomic research in that it has high sensitivity in the low-molecular-weight range and high throughput capability, and proteins with extreme characteristics (highly hydrophobic, acidic, or basic) can be analyzed more easily. With this technique, whole serum is applied to protein chips with different chromatographic affinities in a suitable binding buffer. Selectively bound proteins are retained on the surface, and nonselectively bound proteins are washed off. In the mass spectrometer, a laser desorbs the bound proteins from the chip surface, which are subsequently detected in the time-of-flight (TOF) analyzer by their respective mass-to-charge ratios (m/z). Since a whole pattern of proteins is analyzed, more than 1 biomarker can be detected. The combination of several of these biomarkers for the evaluation of a patient's status may result in enhanced sensitivities and specificities.
Matrix-assisted laser desorption/ionization TOF mass spectrometry (MALDI-TOF MS) is an important proteomic technology. Many protein biomarkers of certain diseases have been indicated by using MALDI-TOF MS to analyze the serum proteome. The goal of this study was to screen for protein biomarkers in serum for the early diagnosis of HCC using MALDI-TOF MS combined with magnetic beads and pattern recognition software.
Materials and Methods

Samples
We collected 242 serum samples from 96 patients with HCC, 68 patients with hepatic disease other than HCC (autoimmune hepatitis, 15; HBV infection, 20; cirrhosis, 31; alcoholic hepatitis, 1; and drug-induced liver disorder, 1), and 78 healthy volunteers. All cases of HCC were diagnosed according to combined clinical criteria, including imaging data and serum tumor markers, and further confirmed by histopathologic analysis. The biopsy samples from 31 patients with cirrhosis were reviewed by 1 pathologist. The patients with cirrhosis had at least 2 years of follow-up from the time serum was obtained for these studies. The follow-up included ultrasound and α-fetoprotein (AFP) every 6 months for at least 2 years with no evidence of development of HCC. Serum samples of 20 HBV-infected patients were collected based on the presence of HBsAg, HBeAg, and HBV DNA, from Taizhou Municipal Hospital, affiliated hospital of Taizhou University (Taizhou, Zhejiang, China). Of the 17 remaining patients with hepatic disease other than HCC (autoimmune hepatitis, 15; alcoholic hepatitis, 1; and drug-induced liver disorder, 1) the diagnosis was also confirmed by histopathologic analysis.
Blood samples were obtained with informed consent from all subjects. The protocol was approved by the review board of Taizhou Municipal Hospital, affiliated hospital of Taizhou University. The 96 patients with HCC were clinically diagnosed according to generally accepted criteria. 9 The blood samples were collected in 5-mL BD Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) without anticoagulation and allowed to clot at room temperature for up to 1 hour; the samples were then centrifuged at 4°C for 5 minutes at 10,000 rpm. The serum samples were frozen and stored at -80°C for future analysis. The patients and serum samples were then divided into 2 groups: the ''training'' set and the blinded ''test'' set ❚Table 1❚.
ProteinChip Analysis
Sample pretreatments and proteomic analysis in the proteomic profiling analysis and the serum samples from the diseased and control groups were randomized, and the investigator was blinded to their identity. Serum samples were pretreated with weak cation exchange (WCX) magnetic beads was discarded carefully by using a pipette. The magnetic beads were then washed twice with 100 μL of binding buffer. Then, 100 μL of the diluted serum sample was added to the activated magnetic beads, mixed, and incubated for 1 hour at 4°C, after which the beads were washed twice with 100 μL of binding buffer. Following binding and washing, the bound proteins were eluted from the magnetic beads using 10 μL of 0.5% trifluoroacetic acid. Then, 5 μL of the eluted sample was diluted 1:2-fold in 5 μL of SPA (saturated solution of sinapinic acid in 50% acetonitrile with 0.5% trifluoroacetic acid). Next, 2 μL of the resulting mixture was aspirated and spotted onto an 8-spot prestructured sample chip (Au-chip, Ciphergen Biosystems, Fremont, CA). After air drying for approximately 5 minutes at room temperature, protein crystals on the chip were scanned with the ProteinChip reader (model PBS IIc, Ciphergen Biosystems) to determine the masses and intensities of all peaks in the m/z range of 1,000 to 50,000. The reader was set up as follows: mass range, 1,000 to 50,000 Da; optimized mass range, 2,000 to 15,000 Da; laser intensity, 210; and laser sensitivity, 9. Mass calibration was performed using an all-in-one peptide reference standard that contained vasopressin (1,084.2 Da), somatostatin (1,637.9 Da), bovine insulin β chain (3,495.9 Da), recombinant human insulin (5,807.6 Da), and hirudin (7,033.6 Da) (Ciphergen Biosystems).
Detection and Statistical Data Analysis
The profiling spectra of serum samples from the training set were normalized using total ion current normalization by the Ciphergen ProteinChip Software (version 3.1). Peak labeling was performed by Biomarker Wizard software, version 3.1 (Ciphergen Biosystems). A 2-sample t test was used to compare mean normalized intensities between the case and control groups. The P value was set at .01 for statistical significance. The intensities of selected peaks were then transferred to Biomarker Pattern Software (BPS; Ciphergen Biosystems) to construct the classification tree of HCC. Briefly, the intensities of the selected peaks were submitted to BPS as a "root note." Based on peak intensity, a threshold was determined by BPS to classify the root node into 2 child nodes. If the peak intensity of a blind sample was lower than or equal to the threshold, this peak would be labeled as "leftside child node." Peak intensities higher than the threshold would be marked as "right-side child node." After rounds of decision making, the training set was found to be discriminatory with the least error.
All protein peak intensities of samples in the test set were evaluated by BPS using the classification model. The HCC and control samples were then discriminated based on their proteomic profile characteristics. The sensitivity was defined as the probability of predicting HCC cases, and the specificity was defined as the probability of predicting control samples. A positive predictive value reflected the probability of HCC if a test result was positive.
Results
Detection of Protein Peaks
Proteomic data from the samples in the training set (consisting of 60 HCCs, 36 hepatic disease, and 46 control samples) were analyzed with Biomarker Wizard software, version 3.1. Up to 238 protein peaks per spot were detected between m/z 1,000 and m/z 50,000, and the protein peaks showed the effectiveness of the MALDI technology separation of lowmolecular-weight proteins (<15,000) ❚Figure 1❚.
Optimization of Experimental Conditions and Evaluation of Reproducibility
Reproducibility was evaluated with 4 mixed serum samples from healthy control subjects with blood type O (2 women and 2 men). The mixed serum samples were spotted on an 8-spot prestructured sample chip. The coefficient of variation was less than 10% for all selected mass peaks ❚Figure 2❚. 
Protein Fingerprint Analysis of Serum Samples in Patients With HCC, Control Subjects With Hepatic Disease, and Healthy Control Subjects
The protein profile of the serum samples from the 60 patients with HCC, the 36 patients with other hepatic diseases, and the 46 healthy control subjects was extracted by magnetic beads and examined by MALDI-TOF MS. The data were analyzed by using Biomarker Wizard, version 3.1; 72 m/z peaks were found to discriminate patients with HCC, patients with other hepatic diseases, and healthy control subjects ❚Table 2❚.
Identification of Biomarker Pattern and Construction of Diagnostic Model
The comparison among different samples showed that the serum profiles from patients with HCC and control subjects were very similar despite a few intersample variations. Therefore, the few variations that consistently differentiate these 3 groups could be considered as potential disease biomarkers. We used the Biomarker Wizard function of ProteinChip software to identify clusters of peaks differentially presented in HCC serum samples compared with samples from patients with other hepatic diseases and healthy control subjects. We obtained 72 discriminating protein peaks in serum samples. To develop biomarker patterns for the diagnosis of HCC, the intensities of the protein peaks in the training set were submitted to BPS. A total of 4 peaks (4,471, 8,936, 11,670, and 13,752 Da) with the highest discriminatory power were automatically selected to construct a classification tree ❚Figure 3❚. ❚Figure 4❚ shows the tree structure and sample distribution. The classification tree using the combination of the 4 peaks identified 60 patients with HCC, 36 patients with other hepatic diseases, and 46 ❚Figure 2❚ An 8-spot test showed good reproducibility. The coefficient of variation (CV) of all selected mass peaks was less than 10%. healthy control subjects with a calculated sensitivity of 93% and a specificity of 95% ❚Table 3❚.
Test of the Diagnostic Model for HCC in a Blind Test
We used 100 samples, including 36 from patients with HCC, 32 from patients with hepatic disease, and 32 from healthy control subjects (Table 1) to test the HCC diagnostic model. The classification tree discriminated the HCC samples from the control samples with a sensitivity of 89% and a specificity of 91% (Table 3 ). The corresponding receiver operating characteristics curve of the optimal decision tree was supplied 4,425 4,450 4,475 4,500  8,900 8,920 8,940 8,960 8,980  11,600 11,700 11,800 11,900  13,600 13,700 13,800 13 by the BPS. The receiver operating characteristic integral was 0.927 ❚Figure 5❚.
Discussion
HCC is a debilitating disease associated with high mortality. Its successful treatment relies on an early diagnosis, but this remains a challenge because the progression of the malignancy is usually silent until it reaches a more advanced stage, when the prognosis is poor. Certainly, early detection can drastically facilitate treatment and improve the long-term survival of patients. 10, 11 The sensitivity of current single biomarkers in tumor diagnosis is low (usually <60%) and complicated by a high return of false-positives. Furthermore, none of the existing serum markers can be used individually for screening for HCC. AFP also seems to have reduced sensitivity for smaller tumors, 12 and some authors argue that it has limited usefulness as a screening test. 13 Recently, the American Association for the Study of Liver Diseases guidelines for HCC screening recognized the overall poor performance of AFP and have removed it from the screening recommendations. 14 It would be highly desirable to have a rapid and sensitive diagnostic test for HCC.
MALDI-TOF MS is a useful tool for integrating separation and analysis of complex mixtures of proteins. Captured proteins are then analyzed by TOF MS, generating a spectral map depicting approximations of the molecular weight (m/z) and relative concentration (intensity) of each protein (ion). The technique is a convenient, high-throughput tool to segregate proteins from complex bodily fluids like serum and generate comparative protein profiles. MALDI technology has now been widely used for the diagnosis of cancer and other diseases in a large number of studies. [15] [16] [17] [18] In our study, WCX magnetic beads were used as a proteome fractionation tool. Strong anionic exchange, hydrophobic/reversed phase, hydrophilic/normal phase, and immobilized metal affinity capture are other magnetic beads available. However, hydrophobic/reversed phase, hydrophilic/normal phase, and immobilized metal affinity capture magnetic beads are directed toward hydrophobic proteins, hydrophilic proteins, and signaling proteins, respectively. WCX magnetic beads could capture more proteins in serum than strong anionic exchange magnetic beads, especially in the low-molecular-weight range (data from our earlier experiment, not shown).
The initial serum proteome profiles of HCC were generated by using MALDI-TOF MS combined with WCX magnetic beads and pattern recognition software in our study. The existence of 72 differential protein peaks between patients with HCC and other subjects indicates that a broad pathologic change of HCC in serum proteome, complements, and unidentified proteins may be involved. Instead of a single protein type, a group of proteins contributes to the pathogenesis of HCC. Based on the differential protein peaks, potential biomarkers specific to HCC are available.
By taking advantage of the recent developments in MALDI and of the WCX magnetic bead (SED) technology, we were able to simultaneously analyze the protein profiles of 142 serum samples from patient with HCC or non-HCC. We identified biomarkers specific for HCC. In our study, Figure 4 shows the tree structure and sample distribution. Four peaks, m/z of 4,471, 8,936, 11,670, and 13,752 Da were chosen to set up the decision tree. 19, 20 At node 1, samples with an m/z of 13,752 with peak intensities lower than or equal to 1.28 went to node 2, which had 34 non-HCC samples and 58 HCC samples. Otherwise, samples entered terminal node 5, which had 48 non-HCC samples and 2 HCC samples. At node 2, samples with an m/z of 8,936 with peak intensities lower than or equal to 2.98 went to node 3, which had 16 non-HCC samples and 56 HCC samples. The other samples entered terminal node 4, which had 18 non-HCC samples and 2 HCC samples. At node 3, samples with an m/z of 4,471 with peak intensities lower than or equal to 0.78 went to terminal node 1, which had 8 non-HCC samples. The other samples went to node 4, which had 8 non-HCC samples and 56 HCC samples. At node 4, samples with an m/z of 11,670 with peak intensities lower than or equal to 2.02 went to terminal node 2, which had 4 non-HCC samples. The other samples entered terminal node 3, which had 4 non-HCC samples and 56 HCC samples. As shown in Table  3 , the model identified 142 samples of the training set, 82 in non-HCC and 60 in HCC, and yielded a sensitivity of 93% and specificity of 95%. In the blinded test set, 58 of 64 true non-HCC cases were correctly classified, and 32 of 36 HCC samples were correctly classified as malignant. These results yield a sensitivity of 89% and a specificity of 91%.
In our diagnostic model, the 4 peaks with different m/z values may be biomarkers unique to HCC or some other disease. The up-regulated candidate protein biomarker (8,936 Da) was identified as fragments of C3a. 21 C3a was reported to be an inflammatory mediator of innate immune responses. 22 Lee et al 23 found that C3a is elevated in patients with chronic hepatitis C and hepatitis C virus-related HCC. Liu et al 24 identified an 11.6-kDa positive protein marker derived from serum amyloid A; its theoretical mass is 11.68 kDa, and the mass of our marker 3 (11.67 kDa) is very similar to that of serum amyloid A. It is a positive marker in severe acute respiratory syndrome 25 and indicates relapse in nasopharyngeal cancer. 26 Serum amyloid A is an acute phase protein that is associated with circulating high-density lipoproteins and that modulates lipid trafficking and immune responses. It is also the precursor protein in reactive amyloidosis. 27 This information will help us in further investigations. The other 2 protein biomarkers (4,471 and 13,752 Da) need to be resolved in future studies. We have shown that using proteomics approaches, such as magnetic beads and MALDI-TOF MS in combination with bioinformatics tools, could facilitate the discovery of new biomarkers and provide a rapid and mass-accurate mode of analysis for the detection of multiple disease-related proteins simultaneously, reproducibly, and in high throughput. By using the panel of 4 selected biomarkers, we could achieve high sensitivity and specificity for the detection of HCC.
